TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals, Inc. (TARS) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D (1.5) | B+ (3.8) | B- (3.1) | B (3.4) | C+ (2.6) | B- (2.9) |
| 2026-11-08 | D (1.5) | B+ (3.8) | B (3.2) | B (3.3) | C+ (2.6) | B- (2.9) |
| 2026-11-01 | B- (3.0) | B+ (3.8) | B+ (3.8) | B+ (3.6) | C+ (2.7) | B (3.4) |
| 2026-10-25 | B- (3.0) | B+ (3.8) | B+ (3.8) | B (3.4) | C+ (2.6) | B (3.3) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe